SAFETY AND EFFICACY OF WF10 AT COVID-19: A PROSPECTIVE CONTROLLED OPEN-LABEL STUDY EFFECT OF WF10 ON CLINICAL OUTCOME OF HOSPITALIZED COVID-19 PATIENTS WITH ELEVATED NEUTROPHIL-LYMPHOCYTE RATIO (NLR) VALUES

This phase IIa study aims to a) prove the safety of WF10 therapy upon application to hospitalized COVID-19 patients with mild to moderate disease severity and to b) test the efficacy of the drug to stop disease progression. The latter aspect will be addressed by determining the ability of WF10 therapy to i) lower elevated NLR values and ii) diminish pneumonia (e.g. terminate shortness of breath episodes and appearance of ARDS). During follow up number of ICU admission and invasive ventilation (IMV/ECMO) will be monitored